肿瘤细胞治疗研究
英文原题：Immunotherapies for Central Nervous System Tumors and their Neurologic Complications.
随着中枢神经系统肿瘤领域开展更多临床试验，我们开始认识到免疫治疗的前景与当前局限性。虽然一部分患者显示出获益，但免疫治疗试验尚未改变中枢神经系统肿瘤的结局，这促使该领域考虑下一代疗法和联合治疗策略。此外，中枢神经系统免疫治疗的新型毒性正在被描述，如肿瘤炎症相关神经毒性。中枢神经系统肿瘤的免疫治疗仍处于早期阶段，并显示出初步前景。然而，中枢神经系统肿瘤的免疫治疗策略需要考虑中枢神经系统的独特生理学以及针对中枢神经系统的治疗相关的相应神经毒性。阐明这两者将为推进中枢神经系统肿瘤安全有效的免疫治疗奠定基础。
探讨中枢神经系统（CNS）肿瘤免疫治疗试验的全貌，包括免疫检查点抑制剂、疫苗疗法、溶瘤病毒和CAR-T 细胞疗法，并探索相应的神经系统毒性谱。
随着中枢神经系统肿瘤领域开展更多临床试验，我们开始认识到免疫治疗的前景与当前局限性。虽然一部分患者显示出获益，但免疫治疗试验尚未改变中枢神经系统肿瘤的结局，这促使该领域考虑下一代疗法和联合治疗策略。此外，中枢神经系统免疫治疗的新型毒性正在被描述，如肿瘤炎症相关神经毒性。中枢神经系统肿瘤的免疫治疗仍处于早期阶段，并显示出初步前景。然而，中枢神经系统肿瘤的免疫治疗策略需要考虑中枢神经系统的独特生理学以及针对中枢神经系统的治疗相关的相应神经毒性。阐明这两者将为推进中枢神经系统肿瘤安全有效的免疫治疗奠定基础。
PURPOSE OF REVIEW: To discuss the landscape of immunotherapy trials for central nervous system (CNS) tumors including immune checkpoint inhibitors, vaccine therapies, oncolytic viruses, and chimeric antigen receptor T-cell therapy as well as explore the corresponding spectrum of neurologic toxicities. RECENT FINDINGS: As more clinical trials are underway in CNS tumors, we are starting to appreciate both the promise of immunotherapy and current limitations. While a subset of patients demonstrate benefit, immunotherapy trials have not transformed CNS tumor outcomes, which prompts the field to consider next generation therapies and combinatorial approaches. In addition, novel toxicities of CNS immunotherapy are being described such as tumor-inflammation associated neurotoxicity. Immunotherapy in CNS tumor is still in its nascent stages and shows early signs of promise. However, immunotherapeutic approaches in CNS tumors need to account for the unique physiology of the CNS and the corresponding neurologic toxicities that are associated with therapies targeting the CNS. Elucidating both will set the stage for advancement of safe and effective immunotherapy for CNS tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
